Enan­ta's NASH drug bare­ly meets main goal in mid-stage study

A pla­toon of drug de­vel­op­ers big and small has long been work­ing on com­bat­ing NASH, a fat­ty liv­er dis­ease that has rav­aged the de­vel­oped world. On Wednes­day, Enan­ta Phar­ma­ceu­ti­cals un­veiled da­ta from a short mid-stage study which sug­gest­ed its liv­er drug had — by a mi­nus­cule mar­gin — met the main goal in NASH pa­tients.

The drug, EDP-305, is a Far­ne­soid X Re­cep­tor (FXR) ag­o­nist, akin to In­ter­cept’s $ICPT obeti­cholic acid, which pro­duced mixed da­ta in a land­mark phase III study. FXR is a nu­clear re­cep­tor and a  cru­cial reg­u­la­tor of bile acid lev­els in the liv­er and small in­tes­tine.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

San Diego, CA, USA